The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ertapenem     (4R,5R,6S)-3-[(3S,5S)-5-[(3...

Synonyms: Invanz, CHEMBL1359, SureCN34454, Invanz (TN), AC-6814, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ertapenem


High impact information on Ertapenem


Chemical compound and disease context of Ertapenem


Biological context of Ertapenem

  • The pharmacokinetics of ertapenem in elderly subjects, while slightly different from those in young adults, do not require a dosage adjustment for elderly patients [13].
  • The effect of protein binding on the antimicrobial activity of ertapenem was evaluated using the bacterial kill rate and concentration-response studies [14].
  • The kinetics for other beta-lactams were similar to those of ertapenem [15].
  • A slightly but significantly decreased AUC for ertapenem was detected for the female volunteers [16].
  • Ertapenem had excellent antibacterial activity in the treatment of experimental meningitis due to penicillin-sensitive and -resistant pneumococci, leading to a decrease of 0.69 +/- 0.17 and 0.59 +/- 0.22 log(10) CFU/ml x h, respectively, in the viable cell counts in the cerebrospinal fluid [17].

Anatomical context of Ertapenem


Associations of Ertapenem with other chemical compounds


Gene context of Ertapenem

  • The IMP-1 metallo-beta-lactamase conferred substantial ertapenem resistance (MIC, 128 microg/ml) in a porin-deficient Klebsiella pneumoniae strain, whereas a MIC of 6 microg/ml was recorded for its porin-expressing revertant [1].
  • In a three-period crossover study (Part A), 26 healthy subjects received single doses of ertapenem administered i.m., i.v. infused over 30 min, and i.v. infused over 120 min [26].
  • In vitro susceptibility of ertapenem by BSAC standardized methodology [27].
  • A critical 1beta-methyl substituent shields the beta-lactam carbonyl group and serves to reduce dehydropeptidase (DHP)-1 catalysed hydrolysis of the beta-lactam, enabling ertapenem to be administered without a DHP-1 inhibitor [28].
  • Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected [29].

Analytical, diagnostic and therapeutic context of Ertapenem

  • The concentrations of the antibiotics in serum and urine were quantified by the agar well diffusion method bioassay and, in addition, for ertapenem only, by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) [16].
  • Ertapenem breakpoints for streptococci have not been established, but an unofficial susceptibility breakpoint of < or =2 microg/ml was adopted for clinical trials to generate corresponding clinical response data for isolates for which MICs were as high as 2 microg/ml [30].
  • The results suggest that the standard 1-g ertapenem dose may not provide adequate drug exposure for any body mass index classification for MICs in excess of 0.25 to 0.5 mug/ml [8].
  • In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains [31].
  • The present microdialysis study was conducted to measure free, protein-unbound ertapenem concentrations in muscle and subcutaneous tissue [20].


  1. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Livermore, D.M., Oakton, K.J., Carter, M.W., Warner, M. Antimicrob. Agents Chemother. (2001) [Pubmed]
  2. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Xuan, D., Banevicius, M., Capitano, B., Kim, M.K., Nightingale, C., Nicolau, D. Antimicrob. Agents Chemother. (2002) [Pubmed]
  3. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Jacoby, G.A., Mills, D.M., Chow, N. Antimicrob. Agents Chemother. (2004) [Pubmed]
  4. Ertapenem: a review of its use in the management of bacterial infections. Curran, M., Simpson, D., Perry, C. Drugs (2003) [Pubmed]
  5. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Szabó, D., Silveira, F., Hujer, A.M., Bonomo, R.A., Hujer, K.M., Marsh, J.W., Bethel, C.R., Doi, Y., Deeley, K., Paterson, D.L. Antimicrob. Agents Chemother. (2006) [Pubmed]
  6. Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model. Deryke, C.A., Banevicius, M.A., Fan, H.W., Nicolau, D.P. Antimicrob. Agents Chemother. (2007) [Pubmed]
  7. Interplay of Efflux System, ampC, and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical Isolates. Quale, J., Bratu, S., Gupta, J., Landman, D. Antimicrob. Agents Chemother. (2006) [Pubmed]
  8. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Chen, M., Nafziger, A.N., Drusano, G.L., Ma, L., Bertino, J.S. Antimicrob. Agents Chemother. (2006) [Pubmed]
  9. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus. Jacqueline, C., Caillon, J., Grossi, O., Le Mabecque, V., Miegeville, A.F., Bugnon, D., Batard, E., Potel, G. Antimicrob. Agents Chemother. (2006) [Pubmed]
  10. Susceptibilities of Propionibacterium acnes Ophthalmic Isolates to Ertapenem, Meropenem, and Cefepime. Shames, R., Satti, F., Vellozzi, E.M., Smith, M.A. J. Clin. Microbiol. (2006) [Pubmed]
  11. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M.P., Tulkens, P.M. J. Antimicrob. Chemother. (2005) [Pubmed]
  12. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae. Hovde, L.B., Rotschafer, S.E., Ibrahim, K.H., Gunderson, B., Hermsen, E.D., Rotschafer, J.C. Diagn. Microbiol. Infect. Dis. (2003) [Pubmed]
  13. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Musson, D.G., Majumdar, A., Holland, S., Birk, K., Xi, L., Mistry, G., Sciberras, D., Muckow, J., Deutsch, P., Rogers, J.D. Antimicrob. Agents Chemother. (2004) [Pubmed]
  14. Effect of ertapenem protein binding on killing of bacteria. Nix, D.E., Matthias, K.R., Ferguson, E.C. Antimicrob. Agents Chemother. (2004) [Pubmed]
  15. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Hoellman, D.B., Kelly, L.M., Credito, K., Anthony, L., Ednie, L.M., Jacobs, M.R., Appelbaum, P.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  16. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Pletz, M.W., Rau, M., Bulitta, J., De Roux, A., Burkhardt, O., Kruse, G., Kurowski, M., Nord, C.E., Lode, H. Antimicrob. Agents Chemother. (2004) [Pubmed]
  17. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Cottagnoud, P., Pfister, M., Cottagnoud, M., Acosta, F., Täuber, M.G. Antimicrob. Agents Chemother. (2003) [Pubmed]
  18. In vitro activity of ertapenem: review of recent studies. Wexler, H.M. J. Antimicrob. Chemother. (2004) [Pubmed]
  19. Intraabdominal tissue concentration of ertapenem. Wittau, M., Wagner, E., Kaever, V., Koal, T., Henne-Bruns, D., Isenmann, R. J. Antimicrob. Chemother. (2006) [Pubmed]
  20. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. Burkhardt, O., Brunner, M., Schmidt, S., Grant, M., Tang, Y., Derendorf, H. J. Antimicrob. Chemother. (2006) [Pubmed]
  21. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Tomera, K.M., Burdmann, E.A., Reyna, O.G., Jiang, Q., Wimmer, W.M., Woods, G.L., Gesser, R.M. Antimicrob. Agents Chemother. (2002) [Pubmed]
  22. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Pankuch, G.A., Davies, T.A., Jacobs, M.R., Appelbaum, P.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  23. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. Livermore, D.M., Mushtaq, S., Warner, M. J. Antimicrob. Chemother. (2005) [Pubmed]
  24. In vitro activity of ertapenem against selected respiratory pathogens. Marchese, A., Gualco, L., Schito, A.M., Debbia, E.A., Schito, G.C. J. Antimicrob. Chemother. (2004) [Pubmed]
  25. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. Tice, A.D. J. Antimicrob. Chemother. (2004) [Pubmed]
  26. Pharmacokinetics of intramuscularly administered ertapenem. Musson, D.G., Majumdar, A., Birk, K., Holland, S., Wickersham, P., Li, S.X., Mistry, G., Fisher, A., Waldman, S., Greenberg, H., Deutsch, P., Rogers, J.D. Antimicrob. Agents Chemother. (2003) [Pubmed]
  27. In vitro susceptibility of ertapenem by BSAC standardized methodology. Andrews, J.M., Ashby, J.P., Jevons, G., Wise, R. J. Antimicrob. Chemother. (2003) [Pubmed]
  28. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. Hammond, M.L. J. Antimicrob. Chemother. (2004) [Pubmed]
  29. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. Nix, D.E., Majumdar, A.K., DiNubile, M.J. J. Antimicrob. Chemother. (2004) [Pubmed]
  30. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Livermore, D.M., Carter, M.W., Bagel, S., Wiedemann, B., Baquero, F., Loza, E., Endtz, H.P., van Den Braak, N., Fernandes, C.J., Fernandes, L., Frimodt-Moller, N., Rasmussen, L.S., Giamarellou, H., Giamarellos-Bourboulis, E., Jarlier, V., Nguyen, J., Nord, C.E., Struelens, M.J., Nonhoff, C., Turnidge, J., Bell, J., Zbinden, R., Pfister, S., Mixson, L., Shungu, D.L. Antimicrob. Agents Chemother. (2001) [Pubmed]
  31. In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains. Decousser, J.W., Methlouthi, I., Pina, P., Allouch, P. J. Antimicrob. Chemother. (2005) [Pubmed]
WikiGenes - Universities